Turner Syndrome Global Market Report 2025

Turner syndrome is a genetic condition affecting females, caused by the partial or complete absence of one X chromosome. It can lead to various developmental and medical challenges, including short stature, delayed puberty, infertility, heart defects, and certain learning difficulties. Diagnosis is typically performed through karyotype testing, and management involves specialized medical care to address associated health concerns.

The main types of Turner syndrome include classical Turner syndrome and mosaic Turner syndrome. Classical Turner syndrome is the most common form, characterized by the complete absence of one X chromosome in females. Treatment options include growth hormone therapy, estrogen and progesterone replacement therapy, and other supportive therapies. Several drugs are used for this condition, including Norditropin, Oxandrolone, Humatrope, Somatropin, Oxandrin, Genotropin, Nutropin, and Zomacton. These treatments are utilized by various end users, such as hospitals, home care settings, specialty clinics, and surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The turner syndrome market research report is one of a series of new reports from The Business Research Company that provides turner syndrome market statistics, including turner syndrome industry global market size, regional shares, competitors with a turner syndrome market share, detailed turner syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the turner syndrome industry. This turner syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The turner syndrome market size has grown strongly in recent years. It will grow from $2.36 billion in 2024 to $2.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing awareness of the women health, rising healthcare expenditure, growing healthcare sector, increasing awareness and early diagnosis of turner syndrome, and public awareness initiatives.

The turner syndrome market size is expected to see strong growth in the next few years. It will grow to $3.39 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rising cases of structural abnormalities of the x chromosome, widespread adoption of estrogen replacement therapy, increasing utilization of chromosomal microarray analysis (cma) for disease diagnosis, increasing female population, increasing research and development activities. Major trends in the forecast period include adoption of new technologies, product launches, advances in growth hormone therapy, demand for hormonal treatments, development of novel therapies.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder pediatric endocrine care by inflating prices of recombinant growth hormone therapies and estrogen patches manufactured in Denmark and Belgium, resulting in delayed puberty management and higher specialty pharmacy expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing female population is expected to drive the growth of the Turner syndrome treatment market. As the global female population expands due to factors such as higher life expectancy, improved healthcare, and demographic shifts, the demand for specialized treatments for Turner syndrome rises. Turner syndrome treatment supports affected individuals through growth hormone therapy to enhance stature, estrogen replacement for puberty induction and bone health maintenance, and multidisciplinary care to manage associated conditions. According to the U.S. Census Bureau, as of July 2022, the United States had approximately 168 million females, with 1.9 million more women aged 85 and older. Additionally, CEIC Data reported in December 2022 that the number of females aged 15-64 had risen from 2,940,645 in 2021 to 2,951,856 in 2022. This demographic trend is contributing to the increased demand for Turner syndrome treatments.

Advancements in pediatric growth hormone therapies are also driving market growth. Major pharmaceutical companies are conducting clinical trials to develop innovative products aimed at improving height outcomes and overall development in children with Turner syndrome and growth-related disorders. Pediatric growth hormone medications, particularly synthetic or recombinant hormones, play a crucial role in stimulating growth in children with deficiencies. For instance, in December 2024, Ascendis Pharma A/S announced positive Phase 2 trial results for TransCon hGH (lonapegsomatropin) in children aged 1-10 years with Turner syndrome. The trial demonstrated that TransCon hGH provided growth improvements comparable to daily somatropin, with a similar safety profile. These promising results could expand the market for growth hormone treatments in Turner syndrome patients.

In December 2024, Double Point Ventures (DPV) acquired Lumos Pharma for $38 million to enhance its portfolio in biopharmaceutical therapeutics for rare diseases. Lumos Pharma's lead candidate, LUM-201, an oral growth hormone secretagogue currently in Phase 2 clinical trials for pediatric growth hormone deficiency, has the potential to impact Turner syndrome treatment. By integrating Lumos Pharma's expertise, DPV aims to drive further innovation in growth hormone therapy and broaden treatment options for patients with Turner syndrome.

Major players in the turner syndrome market are Pfizer Inc., Sanofi SA, AstraZeneca Plc, Abbott Laboratories, Novartis AG, LG Chem Ltd., Eli Lilly and Company, Novo Nordisk, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Pharma, Ferring Pharmaceutical, BioMarin Pharmaceutical Inc., United Imaging Healthcare Co. Ltd., Daewoong Pharmaceutical Co. Ltd., OPKO Health Inc., Hanmi Pharmaceutical Co. Ltd., Dong-A ST Co. Ltd., GeneScience Pharmaceuticals Co. Ltd., Ascendis Pharma, AnkeBio Co. Ltd., Biopartners Inc., Kexing Biopharm Co. Ltd.

North America was the largest region in the turner syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in turner syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the turner syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The turner syndrome market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic testing services, fertility and reproductive health support. The market value includes the value of related goods sold by the service provider or included within the service offering. The turner syndrome market also includes sales of genetic testing kits, cardiac monitoring devices and bone density supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Turner Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on turner syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for turner syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The turner syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Classical Turner Syndrome; Mosaic Turner syndrome
• 2) By Therapy Type: Growth Hormone Therapy; Estrogen And Progesteron; Replacement Therapy; Other Therapy Types
• 3) By Drug Type: Norditropin; Oxandrolone; Humatrope; Somatropin; Oxandrin; Genotropin; Nutropin; Zomacton
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Surgical Centres; Other End-Users
• Subsegments:
• 1) By Classical Turner Syndrome: Complete Monosomy X; X Chromosome Deletion
• 2) By Mosaic Turner Syndrome: Mosaicism With 45,X/46,XX Karyotype; Mosaicism With 45,X/46,XY Karyotype
• Companies Mentioned: Pfizer Inc.; Sanofi SA; AstraZeneca Plc; Abbott Laboratories; Novartis AG; LG Chem Ltd.; Eli Lilly and Company; Novo Nordisk; Merck KGaA; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Genentech Inc.; Ipsen Pharma; Ferring Pharmaceutical; BioMarin Pharmaceutical Inc.; United Imaging Healthcare Co. Ltd.; Daewoong Pharmaceutical Co. Ltd.; OPKO Health Inc.; Hanmi Pharmaceutical Co. Ltd.; Dong-A ST Co. Ltd.; GeneScience Pharmaceuticals Co. Ltd.; Ascendis Pharma; AnkeBio Co. Ltd.; Biopartners Inc.; Kexing Biopharm Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.